Antti Viitala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Antti Viitala has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Jani Saunavaara
Department of Medical Physics, Turku University Hospital, Turku, Finland
3 shared publications - Roberto Blanco Sequeiros
Department of Radiology, Turku University Hospital, University of Turku, 20014 Turku, Finland
3 shared publications - Teija Sainio
FICAN West Cancer Centre University of Turku and Turku University Hospital Turku Finland
3 shared publications - Mikael Anttinen
Department of Urology University of Turku and Turku University hospital Turku Finland
2 shared publications - Pekka Taimen
Institute of Biomedicine and FICAN West Cancer Centre, University of Turku, Turku, Finland
2 shared publications - Peter J. Bostrom
Department of Urology University of Turku and Turku University hospital Turku Finland
2 shared publications
Latest Publications
- Open Access
- 28 May 2025
- Published by Wiley in BJU International
- Vol. 136 (3) , 473-483
Magnetic resonance imaging ‐guided transurethral ultrasound ablation for benign prostatic obstruction: 1‐year clinical outcomes of a phase II study
Objectives: To evaluate the safety and efficacy of magnetic resonance imaging (MRI)‐guided transurethral ultrasound ablation (TULSA) as a minimally invasive alternative for benign prostatic obstruction (BPO). Patients and Methods: This prospective, single‐centre, early phase II study (NCT03350529) included 30 men with BPO scheduled for primary transurethral resection of the prostate. Assessments over 12 months included uroflowmetry, prostate‐specific antigen (PSA) levels, and validated questionnaires at baseline and 3‐month intervals. MRI was performed at baseline and at 3 and 12 months. Medication use and adverse events (AEs) were recorded and graded using the Clavien–Dindo classification. Results: The median patient age at treatment was 67 years. During the 12‐month post‐TULSA follow‐up, prostate volume decreased from a median of 52 to 32 mL, and PSA levels from 3.1 to 1.5 μg/L. The maximum flow rate increased from 11.1 to 18.3 mL/s ( P < 0.001), and the average flow rate from 4.2 to 9.1 mL/s ( P < 0.001). Residual volume decreased from 71 to 40 mL, and voided volume increased from 211 to 301 mL. The International Prostate Symptom Score (IPSS) decreased from 17 to 4 ( P < 0.001), and IPSS quality of life score improved from 4 to 1 ( P < 0.001). The 26‐item Expanded Prostate Cancer Index Composite urinary irritative/obstructive scores improved from 66 to 94 ( P < 0.001), and urinary incontinence scores improved from 86 to 100 ( P = 0.008). Sexual function remained stable or improved. A total of 13 AEs were recorded, including 11 Grade II events (urinary tract infections/retentions) and one Grade IIIb event (epididymitis requiring drainage under general anaesthesia). All AEs resolved during follow‐up. Conclusions: Transurethral ultrasound ablation appears to be a safe and effective experimental treatment for BPO, demonstrating clinically marked improvements in urinary function and quality of life at 12 months while preserving continence and sexual functions. However, it is not yet recommended by guidelines, and long‐term outcomes and validation in larger cohorts remain essential.
- 28 May 2025
- Published by Wiley in BJU International
- Vol. 136 (3) , 473-483
Open AccessMagnetic resonance imaging ‐guided transurethral ultrasound ablation for benign prostatic obstruction: 1‐year clinical outcomes of a phase II study
Objectives: To evaluate the safety and efficacy of magnetic resonance imaging (MRI)‐guided transurethral ultrasound ablation (TULSA) as a minimally invasive alternative for benign prostatic obstruction (BPO). Patients and Methods: This prospective, single‐centre, early phase II study (NCT03350529) included 30 men with BPO scheduled for primary transurethral resection of the prostate. Assessments over 12 months included uroflowmetry, prostate‐specific antigen (PSA) levels, and validated questionnaires at baseline and 3‐month intervals. MRI was performed at baseline and at 3 and 12 months. Medication use and adverse events (AEs) were recorded and graded using the Clavien–Dindo classification. Results: The median patient age at treatment was 67 years. During the 12‐month post‐TULSA follow‐up, prostate volume decreased from a median of 52 to 32 mL, and PSA levels from 3.1 to 1.5 μg/L. The maximum flow rate increased from 11.1 to 18.3 mL/s ( P < 0.001), and the average flow rate from 4.2 to 9.1 mL/s ( P < 0.001). Residual volume decreased from 71 to 40 mL, and voided volume increased from 211 to 301 mL. The International Prostate Symptom Score (IPSS) decreased from 17 to 4 ( P < 0.001), and IPSS quality of life score improved from 4 to 1 ( P < 0.001). The 26‐item Expanded Prostate Cancer Index Composite urinary irritative/obstructive scores improved from 66 to 94 ( P < 0.001), and urinary incontinence scores improved from 86 to 100 ( P = 0.008). Sexual function remained stable or improved. A total of 13 AEs were recorded, including 11 Grade II events (urinary tract infections/retentions) and one Grade IIIb event (epididymitis requiring drainage under general anaesthesia). All AEs resolved during follow‐up. Conclusions: Transurethral ultrasound ablation appears to be a safe and effective experimental treatment for BPO, demonstrating clinically marked improvements in urinary function and quality of life at 12 months while preserving continence and sexual functions. However, it is not yet recommended by guidelines, and long‐term outcomes and validation in larger cohorts remain essential.
- Open Access
- 23 June 2021
- Published by Wiley in BJU International
- Vol. 129 (2) , 208-216
Magnetic resonance imaging‐guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12‐month clinical outcomes of a phase I study
Objectives: To investigate the safety and feasibility of magnetic resonance imaging (MRI)‐guided transurethral ultrasound ablation (TULSA) for the treatment of benign prostatic obstruction (BPO). Patients and methods: An investigator‐initiated, prospective, registered (NCT03350529), phase I study enrolled men with lower urinary tract symptoms due to benign prostatic hyperplasia in need of surgical intervention. Patients were followed for 12 months after TULSA. Uroflowmetry, prostate‐specific antigen (PSA) level, and a comprehensive set of functional questionnaires including the Expanded Prostate cancer Index Composite‐26, International Prostate Symptom Score (IPSS) and five‐item version of the International Index of Erectile Function were obtained at baseline and every 3 months afterwards. MRI was obtained at baseline, and at 3 and 12 months after TULSA. Medication use before and after TULSA were recorded. Adverse events (AEs) were reported using the Clavien–Dindo classification. Results: A total of 10 men underwent TULSA with no severe AEs encountered. The baseline median (interquartile range [IQR]) age and prostate volume were 68 (63–72) years and 53 (45–66) mL, respectively. At baseline, six patients were moderately symptomatic and four patients severely symptomatic. Nine patients at baseline were on BPO medication. The median (IQR) improvement in the IPSS was 82%, from 17.5 (15.3–23.0) at baseline to 4.0 (2.3–6.3) at 12 months. Similarly, the median maximum urinary flow rate improved by 101%, from a median (IQR) of 12.4 (8.8–17.6) mL/s at baseline to 21.8 (17.6–26.5) mL/s at 12 months. Improvements were already seen at 3 months. The median prostate volume and PSA reduction at 12 months were 33% and 48%, respectively. There were no changes in continence, sexual, erectile or bowel functions. At 12 months, five out of six men with normal ejaculatory function before TULSA reported normal antegrade ejaculations. All patients taking BPO medication before TULSA discontinued medication after TULSA. Conclusion: TULSA appears to be a safe and effective treatment for BPO, with promising 12‐month follow‐up outcomes. Further studies with larger cohorts are needed to confirm the observed results.
- 23 June 2021
- Published by Wiley in BJU International
- Vol. 129 (2) , 208-216
Open AccessMagnetic resonance imaging‐guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12‐month clinical outcomes of a phase I study
Objectives: To investigate the safety and feasibility of magnetic resonance imaging (MRI)‐guided transurethral ultrasound ablation (TULSA) for the treatment of benign prostatic obstruction (BPO). Patients and methods: An investigator‐initiated, prospective, registered (NCT03350529), phase I study enrolled men with lower urinary tract symptoms due to benign prostatic hyperplasia in need of surgical intervention. Patients were followed for 12 months after TULSA. Uroflowmetry, prostate‐specific antigen (PSA) level, and a comprehensive set of functional questionnaires including the Expanded Prostate cancer Index Composite‐26, International Prostate Symptom Score (IPSS) and five‐item version of the International Index of Erectile Function were obtained at baseline and every 3 months afterwards. MRI was obtained at baseline, and at 3 and 12 months after TULSA. Medication use before and after TULSA were recorded. Adverse events (AEs) were reported using the Clavien–Dindo classification. Results: A total of 10 men underwent TULSA with no severe AEs encountered. The baseline median (interquartile range [IQR]) age and prostate volume were 68 (63–72) years and 53 (45–66) mL, respectively. At baseline, six patients were moderately symptomatic and four patients severely symptomatic. Nine patients at baseline were on BPO medication. The median (IQR) improvement in the IPSS was 82%, from 17.5 (15.3–23.0) at baseline to 4.0 (2.3–6.3) at 12 months. Similarly, the median maximum urinary flow rate improved by 101%, from a median (IQR) of 12.4 (8.8–17.6) mL/s at baseline to 21.8 (17.6–26.5) mL/s at 12 months. Improvements were already seen at 3 months. The median prostate volume and PSA reduction at 12 months were 33% and 48%, respectively. There were no changes in continence, sexual, erectile or bowel functions. At 12 months, five out of six men with normal ejaculatory function before TULSA reported normal antegrade ejaculations. All patients taking BPO medication before TULSA discontinued medication after TULSA. Conclusion: TULSA appears to be a safe and effective treatment for BPO, with promising 12‐month follow‐up outcomes. Further studies with larger cohorts are needed to confirm the observed results.
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S71
MRI-guided transurethral ultrasound ablation for treatment of benign prostatic obstruction
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S71
MRI-guided transurethral ultrasound ablation for treatment of benign prostatic obstruction
- Open Access
- 28 November 2018
- Published by Springer Nature in Journal of Therapeutic Ultrasound
- Vol. 6 (1) , 10
Wedged gel pad for bowel manipulation during MR-guided high-intensity focused ultrasound therapy to treat uterine fibroids: a case report
Magnetic resonance guided high-intensity focused ultrasound (MR-HIFU) therapy is not feasible in all patients with uterine fibroids because of limiting anatomical factors such as scar tissue, bowel loops or other obstacles in the sonication path. These may prevent the treatment or limit the treatment window, and therefore, also the volume where HIFU therapy can be delivered. Bowel loops present a particular problem because of bowel gas bubbles and hard particles which may cause reflection or absorption of ultrasound energy, potentially leading to thermal damage and even bowel perforation. Most commonly used techniques for bowel repositioning are bladder and/or rectum filling but these are not always sufficient to reposition the bowel loops. With more efficient bowel repositioning technique, the number of eligible patients for MR-HIFU treatment could be increased, and therapy efficacy be improved in cases where bowel loops limit the treatment window. A wedged exterior gel pad was used in two patients presented with in total of four symptomatic fibroids undergoing MR-HIFU treatment when bladder and/or rectum filling was not sufficient to reposition the bowel loops. No severe adverse effects were observed in these cases. The non-perfused volume ratios (NPVs) immediately after treatment were 86% and 39% for the first patient, and 3% for the second patient. Our preliminary experience suggests that the use of a wedged gel pad during MR-HIFU treatment could be an effective tool to manipulate the bowels in cases where the bladder and/or rectum filling is not sufficient to reposition the bowel loops. A wedged gel pad could also be used in other situations to achieve better treatment coverage to the uterine fibroid.
- 28 November 2018
- Published by Springer Nature in Journal of Therapeutic Ultrasound
- Vol. 6 (1) , 10
Open AccessWedged gel pad for bowel manipulation during MR-guided high-intensity focused ultrasound therapy to treat uterine fibroids: a case report
Magnetic resonance guided high-intensity focused ultrasound (MR-HIFU) therapy is not feasible in all patients with uterine fibroids because of limiting anatomical factors such as scar tissue, bowel loops or other obstacles in the sonication path. These may prevent the treatment or limit the treatment window, and therefore, also the volume where HIFU therapy can be delivered. Bowel loops present a particular problem because of bowel gas bubbles and hard particles which may cause reflection or absorption of ultrasound energy, potentially leading to thermal damage and even bowel perforation. Most commonly used techniques for bowel repositioning are bladder and/or rectum filling but these are not always sufficient to reposition the bowel loops. With more efficient bowel repositioning technique, the number of eligible patients for MR-HIFU treatment could be increased, and therapy efficacy be improved in cases where bowel loops limit the treatment window. A wedged exterior gel pad was used in two patients presented with in total of four symptomatic fibroids undergoing MR-HIFU treatment when bladder and/or rectum filling was not sufficient to reposition the bowel loops. No severe adverse effects were observed in these cases. The non-perfused volume ratios (NPVs) immediately after treatment were 86% and 39% for the first patient, and 3% for the second patient. Our preliminary experience suggests that the use of a wedged gel pad during MR-HIFU treatment could be an effective tool to manipulate the bowels in cases where the bladder and/or rectum filling is not sufficient to reposition the bowel loops. A wedged gel pad could also be used in other situations to achieve better treatment coverage to the uterine fibroid.
- Open Access
- 11 August 2016
- Published by Springer Nature in Journal of Therapeutic Ultrasound
- Vol. 4 (1) , 20
Volumetric MR-guided high-intensity focused ultrasound ablation to treat uterine fibroids through the abdominal scars using scar patch: a case report
Abdominal scars pose a challenge in magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) therapies, limiting patient selection and increasing the risk of skin burns. Especially, scars arising from longitudinal incisions are problematic as they usually lie medially at the lower abdomen where the ultrasound beam has to go through. Volumetric sonication has been shown to efficiently enlarge the ablated volume per sonication, but they nevertheless require more thermal energy to be deposited per sonication which increases the temperature in the near-field area located between the transducer and the target region. The scar patch was used in three patients undergoing MR-HIFU ablation of fibroids using volumetric technique, one with transverse incision and the other two with longitudinal incision. No severe adverse effects were observed. The relative shrinkage of the fibroid of these patients at 6-month follow-up were 67, 78, and 59 %, respectively. Our preliminary experience suggests that the use of scar patch on MR-HIFU ablation of fibroids using volumetric technique provides an effective treatment option for patients who were previously excluded from MR-HIFU treatment due to the abdominal scars.
- 11 August 2016
- Published by Springer Nature in Journal of Therapeutic Ultrasound
- Vol. 4 (1) , 20
Open AccessVolumetric MR-guided high-intensity focused ultrasound ablation to treat uterine fibroids through the abdominal scars using scar patch: a case report
Abdominal scars pose a challenge in magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) therapies, limiting patient selection and increasing the risk of skin burns. Especially, scars arising from longitudinal incisions are problematic as they usually lie medially at the lower abdomen where the ultrasound beam has to go through. Volumetric sonication has been shown to efficiently enlarge the ablated volume per sonication, but they nevertheless require more thermal energy to be deposited per sonication which increases the temperature in the near-field area located between the transducer and the target region. The scar patch was used in three patients undergoing MR-HIFU ablation of fibroids using volumetric technique, one with transverse incision and the other two with longitudinal incision. No severe adverse effects were observed. The relative shrinkage of the fibroid of these patients at 6-month follow-up were 67, 78, and 59 %, respectively. Our preliminary experience suggests that the use of scar patch on MR-HIFU ablation of fibroids using volumetric technique provides an effective treatment option for patients who were previously excluded from MR-HIFU treatment due to the abdominal scars.
- 1 February 2014
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 202 (2) , 443-451
Techniques to Expand Patient Selection for MRI-Guided High-Intensity Focused Ultrasound Ablation of Uterine Fibroids
MRI-guided high-intensity focused ultrasound (HIFU) ablation is increasingly adopted for treating symptomatic uterine fibroids. As a noninvasive therapy performed on an outpatient basis, it has been viewed by patients to have distinct advantages over other treatment options. However, its breadth of clinical application is still limited. To address this issue, various techniques have been implemented. In this article, we discuss techniques that contribute to widening patient selection for MRI-guided HIFU therapy of uterine fibroids.
- 1 February 2014
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 202 (2) , 443-451
Techniques to Expand Patient Selection for MRI-Guided High-Intensity Focused Ultrasound Ablation of Uterine Fibroids
MRI-guided high-intensity focused ultrasound (HIFU) ablation is increasingly adopted for treating symptomatic uterine fibroids. As a noninvasive therapy performed on an outpatient basis, it has been viewed by patients to have distinct advantages over other treatment options. However, its breadth of clinical application is still limited. To address this issue, various techniques have been implemented. In this article, we discuss techniques that contribute to widening patient selection for MRI-guided HIFU therapy of uterine fibroids.
- 23 May 2012
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 28 (4) , 320-336
Mild hyperthermia with magnetic resonance-guided high-intensity focused ultrasound for applications in drug delivery
Purpose: Mild hyperthermia (40–45°C) is a proven adjuvant for radiotherapy and chemotherapy. Magnetic resonance guided high intensity focused ultrasound (MR-HIFU) can non-invasively heat solid tumours under image guidance. Low temperature-sensitive liposomes (LTSLs) release their drug cargo in response to heat (>40°C) and may improve drug delivery to solid tumours when combined with mild hyperthermia. The objective of this study was to develop and implement a clinically relevant MR-HIFU mild hyperthermia heating algorithm for combination with LTSLs. Materials and methods: Sonications were performed with a clinical MR-HIFU platform in a phantom and rabbits bearing VX2 tumours (target = 4–16 mm). A binary control algorithm was used for real-time mild hyperthermia feedback control (target = 40–41°C). Drug delivery with LTSLs was measured with HPLC. Data were compared to simulation results and analysed for spatial targeting accuracy (offset), temperature accuracy (mean), homogeneity of heating (standard deviation (SD), T10 and T90), and thermal dose (CEM43). Results: Sonications in a phantom resulted in better temperature control than in vivo. Sonications in VX2 tumours resulted in mean temperatures between 40.4°C and 41.3°C with a SD of 1.0–1.5°C (T10 = 41.7–43.7°C, T90 = 39.0–39.6°C), in agreement with simulations. 3D spatial offset was 0.1–3.2 mm in vitro and 0.6–4.8 mm in vivo. Combination of MR-HIFU hyperthermia and LTSLs demonstrated heterogeneous delivery to a partially heated VX2 tumour, as expected. Conclusions: An MR-HIFU mild hyperthermia heating algorithm was developed, resulting in accurate and homogeneous heating within the targeted region in vitro and in vivo, which is suitable for applications in drug delivery.
- 23 May 2012
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 28 (4) , 320-336
Mild hyperthermia with magnetic resonance-guided high-intensity focused ultrasound for applications in drug delivery
Purpose: Mild hyperthermia (40–45°C) is a proven adjuvant for radiotherapy and chemotherapy. Magnetic resonance guided high intensity focused ultrasound (MR-HIFU) can non-invasively heat solid tumours under image guidance. Low temperature-sensitive liposomes (LTSLs) release their drug cargo in response to heat (>40°C) and may improve drug delivery to solid tumours when combined with mild hyperthermia. The objective of this study was to develop and implement a clinically relevant MR-HIFU mild hyperthermia heating algorithm for combination with LTSLs. Materials and methods: Sonications were performed with a clinical MR-HIFU platform in a phantom and rabbits bearing VX2 tumours (target = 4–16 mm). A binary control algorithm was used for real-time mild hyperthermia feedback control (target = 40–41°C). Drug delivery with LTSLs was measured with HPLC. Data were compared to simulation results and analysed for spatial targeting accuracy (offset), temperature accuracy (mean), homogeneity of heating (standard deviation (SD), T10 and T90), and thermal dose (CEM43). Results: Sonications in a phantom resulted in better temperature control than in vivo. Sonications in VX2 tumours resulted in mean temperatures between 40.4°C and 41.3°C with a SD of 1.0–1.5°C (T10 = 41.7–43.7°C, T90 = 39.0–39.6°C), in agreement with simulations. 3D spatial offset was 0.1–3.2 mm in vitro and 0.6–4.8 mm in vivo. Combination of MR-HIFU hyperthermia and LTSLs demonstrated heterogeneous delivery to a partially heated VX2 tumour, as expected. Conclusions: An MR-HIFU mild hyperthermia heating algorithm was developed, resulting in accurate and homogeneous heating within the targeted region in vitro and in vivo, which is suitable for applications in drug delivery.
- 1 February 2009
- Published by SAGE Publications in Acta Radiologica
- Vol. 50 (1) , 114-124
Organ doses and effective doses in pediatric radiography: Patient-dose survey in finland
Background: Use of the effective dose in diagnostic radiology permits the radiation exposure of diverse diagnostic procedures to be quantified. Fundamental knowledge of patient doses enhances the implementation of the “as low as reasonably achievable” (ALARA) principle. Purpose: To provide comparative information on pediatric examination protocols and patient doses in skull, sinus, chest, abdominal, and pelvic radiography examinations. Material and Methods: 24 Finnish hospitals were asked to register pediatric examination data, including patient information and examination parameters and specifications. The total number of examinations in the study was 1916 (1426 chest, 228 sinus, 96 abdominal, 94 skull, and 72 pelvic examinations). Entrance surface dose (ESD) and dose-area products (DAP) were calculated retrospectively or DAP meters were used. Organ doses and effective doses were determined using a Monte Carlo program (PCXMC). Results: There was considerable variation in examination protocols between different hospitals, indicating large variations in patient doses. Mean effective doses of different age groups ranged from 5 µSv to 14 µSv in skull and sinus examinations, from 25 µSv to 483 µSv in abdominal examinations, and from 6 µSv to 48 µSv in chest examinations. Conclusion: In chest and sinus examinations, the amount of data was extensive, allowing national pediatric diagnostic reference levels to be defined. Parameter selection in pediatric examination protocols should be harmonized in order to reduce patient doses and improve optimization.
- 1 February 2009
- Published by SAGE Publications in Acta Radiologica
- Vol. 50 (1) , 114-124
Organ doses and effective doses in pediatric radiography: Patient-dose survey in finland
Background: Use of the effective dose in diagnostic radiology permits the radiation exposure of diverse diagnostic procedures to be quantified. Fundamental knowledge of patient doses enhances the implementation of the “as low as reasonably achievable” (ALARA) principle. Purpose: To provide comparative information on pediatric examination protocols and patient doses in skull, sinus, chest, abdominal, and pelvic radiography examinations. Material and Methods: 24 Finnish hospitals were asked to register pediatric examination data, including patient information and examination parameters and specifications. The total number of examinations in the study was 1916 (1426 chest, 228 sinus, 96 abdominal, 94 skull, and 72 pelvic examinations). Entrance surface dose (ESD) and dose-area products (DAP) were calculated retrospectively or DAP meters were used. Organ doses and effective doses were determined using a Monte Carlo program (PCXMC). Results: There was considerable variation in examination protocols between different hospitals, indicating large variations in patient doses. Mean effective doses of different age groups ranged from 5 µSv to 14 µSv in skull and sinus examinations, from 25 µSv to 483 µSv in abdominal examinations, and from 6 µSv to 48 µSv in chest examinations. Conclusion: In chest and sinus examinations, the amount of data was extensive, allowing national pediatric diagnostic reference levels to be defined. Parameter selection in pediatric examination protocols should be harmonized in order to reduce patient doses and improve optimization.